XFOR
X4 Pharmaceuticals Inc (XFOR)
Healthcare • NASDAQ • $2.59-1.89%
- Symbol
- XFOR
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $2.59
- Daily Change
- -1.89%
- Market Cap
- $256.79M
- Trailing P/E
- 129.50
- Forward P/E
- -3.37
- 52W High
- $4.83
- 52W Low
- $2.43
- Analyst Target
- $11.60
- Dividend Yield
- 0.00%
- Beta
- 0.46
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all th…
Company websiteResearch XFOR on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.